October 10, 2025 — TempraMed Technologies Ltd. has finalized its reverse takeover by TempraMed Israel Ltd. and obtained conditional approval to list its common shares on the Canadian Securities Exchange (CSE), effective September 29, 2025. The British Columbia Securities Commission issued a receipt for the final long form prospectus dated September 25, 2025, making the company a reporting issuer in British Columbia.
The transaction involved the issuance of 40,178,190 TempraMed Shares, 5,740,286 TempraMed Warrants, and 8,000,000 contingent rights in exchange for all outstanding ordinary shares of TempraMed. The company also entered into an escrow agreement dated September 25, 2025, with its transfer agent, Endeavor Trust Corporation, and various securityholders.
Listing on the CSE is contingent upon fulfilling certain requirements, including appointing an independent director residing in Canada who is acceptable to the CSE.
Private placement offerings of 6,618,156 subscription receipts of the Company have been satisfied and the Liquidity Event for the private placement offerings 5,366,348 convertible debentures of the Company (the “Convertible Debentures”) has been completed.
The Convertible Debentures were converted on September 29, 2025, for no additional consideration and with no further action by the holders thereof, into 5,366,348 TempraMed Shares, and the Subscription Receipts were converted into 6,618,156 TempraMed Shares and 6,618,156 common share purchase warrants of the Company (the “TempraMed Warrants”), each of which entitles the holder thereof to acquire one TempraMed Share for $1.00 until March 29, 2027.
The company’s board of directors approved the adoption of an equity incentive plan on September 29, 2025, granting 7,094,856 incentive stock options and 4,497,207 restricted share units.
TempraMed Technologies Ltd. is a global leader in innovative, temperature-controlled medication storage solutions. Investors can contact the company at ir@tempramed.com.
Investor Contacts:
Julia Becker
Vice President, Capital Markets
T: +1 (604) 785-0850
E: julia@tempramed.com
Source: TempraMed Technologies Ltd.
